[go: up one dir, main page]

MA31710B1 - (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament - Google Patents

(carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament

Info

Publication number
MA31710B1
MA31710B1 MA32711A MA32711A MA31710B1 MA 31710 B1 MA31710 B1 MA 31710B1 MA 32711 A MA32711 A MA 32711A MA 32711 A MA32711 A MA 32711A MA 31710 B1 MA31710 B1 MA 31710B1
Authority
MA
Morocco
Prior art keywords
phenloxamide
carboxylalkylphenyl
drug
production processes
compounds
Prior art date
Application number
MA32711A
Other languages
Arabic (ar)
English (en)
Inventor
Elisabeth Defossa
Thomas Klabunde
Viktoria Dietrich
Siegfried Stengelin
Guido Haschke
Andreas Herling
Johanna Kuhlmann
Stefan Bartoschek
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA31710B1 publication Critical patent/MA31710B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des bis-phényl-oxalamides ainsi que leurs sels physiologiquement acceptables. La présente invention concerne des composés de la formule (i), dans laquelle rl, r2, r3, r4, r5, r6, r7, r8, m et x ont les significations indiquées, ainsi que les sels physiologiquement acceptables des composés de formule (i). Les composés sont par exemple appropriés pour le traitement du diabète.
MA32711A 2007-09-21 2010-03-19 (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament MA31710B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07291132 2007-09-21
PCT/EP2008/007218 WO2009039943A1 (fr) 2007-09-21 2008-09-04 (carboxyalkylène-phényl)-phényl-oxalamides, procédé pour leur fabrication et leur utilisation comme médicaments

Publications (1)

Publication Number Publication Date
MA31710B1 true MA31710B1 (fr) 2010-09-01

Family

ID=39111451

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32711A MA31710B1 (fr) 2007-09-21 2010-03-19 (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament

Country Status (20)

Country Link
US (2) US8518875B2 (fr)
EP (1) EP2203416B1 (fr)
JP (1) JP5427784B2 (fr)
KR (1) KR20100061692A (fr)
CN (1) CN101796017A (fr)
AR (1) AR068479A1 (fr)
AU (1) AU2008303976B9 (fr)
CA (1) CA2700028A1 (fr)
CL (1) CL2008002742A1 (fr)
CO (1) CO6260062A2 (fr)
IL (1) IL204555A0 (fr)
MA (1) MA31710B1 (fr)
MX (1) MX2010002461A (fr)
MY (1) MY149648A (fr)
NZ (1) NZ584049A (fr)
RU (1) RU2488578C2 (fr)
TW (1) TWI439265B (fr)
UY (1) UY31350A1 (fr)
WO (1) WO2009039943A1 (fr)
ZA (1) ZA201001015B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20121639A1 (es) 2009-12-25 2012-12-02 Mochida Pharm Co Ltd Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012030165A2 (fr) 2010-08-31 2012-03-08 서울대학교산학협력단 Utilisation de la reprogrammation fœtale d'un agoniste des ppar δ
CA2813639A1 (fr) 2010-10-08 2012-04-12 Mochida Pharmaceutical Co. Ltd. Derive d'amide cyclique
AU2012248629A1 (en) 2011-04-27 2013-11-28 Mochida Pharmaceutical Co., Ltd. Novel 3-hydroxyisothiazole 1-oxide derivative
CA2834465A1 (fr) 2011-04-28 2012-11-01 Mochida Pharmaceutical Co., Ltd. Derive d'amide cyclique
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2013102626A1 (fr) * 2012-01-04 2013-07-11 Sanofi Acides 3-[4-(phénylamino oxalyl amino) phényl] hex-4-énoïques, leur procédé de préparation et leur utilisation comme médicament
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
JPWO2015046317A1 (ja) * 2013-09-30 2017-03-09 国立大学法人 岡山大学 新規アセチレンアミド誘導体
US9957219B2 (en) 2013-12-04 2018-05-01 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
WO2016151018A1 (fr) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode et composition pharmaceutique destinées à être utilisées dans le traitement du diabète
CN111712494A (zh) 2018-02-13 2020-09-25 吉利德科学公司 Pd-1/pd-l1抑制剂
EP4600247A3 (fr) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Inhibiteurs de pd-1/pd-l1
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2021071837A1 (fr) 2019-10-07 2021-04-15 Kallyope, Inc. Agonistes de gpr119
WO2021110076A1 (fr) * 2019-12-04 2021-06-10 深圳信立泰药业股份有限公司 Dérivés d'oxamide, leur procédé de préparation et leur utilisation en médecine
BR112022017039A2 (pt) 2020-02-28 2022-11-16 Kallyope Inc Agonistas de gpr40
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1618196B1 (de) * 1966-02-07 1971-12-09 Ciba Geigy Verwendung von asymmetrischen Oxalsäure-diarylamiden als Ultraviolettschutzmittel
FR2727114B1 (fr) * 1994-11-17 1996-12-27 Oreal Nouveaux filtres solaires, compositions cosmetiques photoprotectrices les contenant et utilisations
DE04029691T1 (de) * 1998-02-02 2007-11-08 Trustees Of Tufts College, Medford Verwendung von Dipetidylpeptidasehemmer zur Regulierung des Glukosemetabolismus
US6890568B2 (en) * 1999-05-24 2005-05-10 Grant Pierce Method for management of blood glucose levels
US6867299B2 (en) * 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
EP1395561A1 (fr) * 2001-05-25 2004-03-10 Boehringer Ingelheim Pharmaceuticals Inc. Composes de carbamate et d'oxamide inhibant la production de cytokine
ITRM20020016A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
JP4224979B2 (ja) * 2002-04-09 2009-02-18 大正製薬株式会社 インターロイキン１２抑制剤
WO2004002481A1 (fr) * 2002-06-27 2004-01-08 Novo Nordisk A/S Activateurs de la glycokinase
US20050124667A1 (en) * 2003-10-30 2005-06-09 Eric Sartori Oxamide inhibitors of plasminogen activator inhibitor-1

Also Published As

Publication number Publication date
CA2700028A1 (fr) 2009-04-02
AU2008303976B2 (en) 2013-04-18
US20100261645A1 (en) 2010-10-14
EP2203416A1 (fr) 2010-07-07
RU2010115748A (ru) 2011-10-27
ZA201001015B (en) 2010-10-27
UY31350A1 (es) 2009-04-30
RU2488578C2 (ru) 2013-07-27
AU2008303976A1 (en) 2009-04-02
EP2203416B1 (fr) 2016-10-26
TW200927088A (en) 2009-07-01
US8518875B2 (en) 2013-08-27
CN101796017A (zh) 2010-08-04
JP5427784B2 (ja) 2014-02-26
TWI439265B (zh) 2014-06-01
JP2010539199A (ja) 2010-12-16
CO6260062A2 (es) 2011-03-22
MX2010002461A (es) 2010-03-26
IL204555A0 (en) 2010-11-30
AU2008303976B9 (en) 2013-09-12
CL2008002742A1 (es) 2009-01-16
MY149648A (en) 2013-09-30
US20130231388A1 (en) 2013-09-05
AR068479A1 (es) 2009-11-18
WO2009039943A1 (fr) 2009-04-02
KR20100061692A (ko) 2010-06-08
NZ584049A (en) 2011-05-27

Similar Documents

Publication Publication Date Title
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA31979B1 (fr) (cyclopropylphenyl) phenyloxamides, leur procede de production et leur utilisation comme medicament
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
TN2009000450A1 (fr) Derives de pyridine
MA30609B1 (fr) Imidazolidine-2,4-diones arylaminoaryl-alkyl-substituees, leur procede de synthese, les medicaments comprenant ces composes, et leurs applications.
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
TNSN07022A1 (fr) Derives de pyridine
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
MA35184B1 (fr) Antagonistes de trpv4
MA29926B1 (fr) Derives de pyrazine
MA30402B1 (fr) Acides carboxyliques substitues par des phenylamino-benzoxazoles, leur procede de production et leur utilisation comme medicaments
MA34397B1 (fr) Dérivés d'acide napht-2-ylacétique dans le traitement du sida
CY1110900T1 (el) Χημικες ενωσεις
CY1108275T1 (el) Χημικες ενωσεις
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
MA38661A1 (fr) Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
MA37886A1 (fr) Nouvelles pyridinones bicycliques
MA38315B1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MA31170B1 (fr) Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine